Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329330 | PMC |
| http://dx.doi.org/10.1513/AnnalsATS.202410-1045RL | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Lung and systemic sclerosis].
Rev Med Interne
August 2025
Inserm, service de médecine interne et immunologie clinique, Centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte du Nord et Nord-Ouest, méditerranée, Guadeloupe (CeRAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation,
Interstitial lung disease (ILD) is a frequent and potentially life-threatening complication of systemic sclerosis, affecting 40 to 50% of patients. Systematic screening with high-resolution computed tomography and pulmonary function tests (PFTs), including DLCO, is recommended at diagnosis. ILD may be present even in patients with normal PFTs.
View Article and Find Full Text PDFUpdated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology Recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease.
Autoimmun Rev
August 2025
University of Modena and Reggio Emilia, Italy; Rheumatology Unit, AUSL-IRCCS Reggio Emilia, Italy.
Background: rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Despite recent guideline initiatives, no treatment recommendations specifically tailored to RA-ILD have been developed in Italy. This systematic literature review (SLR) and meta-analysis was conducted to inform the Italian Society of Rheumatology (SIR) national recommendations for the management of RA-ILD.
View Article and Find Full Text PDFSignificant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope.
Curr Vasc Pharmacol
August 2025
Department of Cardiology, Hippokrateio University Hospital, Athens Greece.
Over the last few decades, there has been noteworthy long-lasting stagnancy in the field of antiarrhythmic drugs (AAD), with the development of novel AAD notably declining over the years. Although ablation therapy has dominated, there remains an unmet need for effective and safe antiarrhythmic therapy in those choosing a conservative approach and those failing the ablation procedure( s). Also, in patients with life-threatening ventricular arrhythmias, in the era of the implantable cardioverter defibrillator dominance, many patients require effective and safe AAD therapy to mitigate the recurrence of arrhythmias and the delivery of painful and unpleasant device shocks.
View Article and Find Full Text PDFAcute thrombocytopenia and fibrinogen reduction occurring after nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report.
Front Oncol
August 2025
Oncology Department, The Second Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, China.
Background: Nintedanib, a small molecule multi-target tyrosine kinase inhibitor, can block the fibrosis process and slow disease progression. Acute thrombocytopenia and fibrinogen reduction caused by nintedanib is a rare clinical event, with few studies reported.
Case Presentation: We report the case of an 89-year-old male diagnosed with advanced renal cell carcinoma who developed immune-related interstitial lung disease after treatment with sintilimab injection combined with axitinib.
Harnessing TP73‑targeted nintedanib: A novel strategy to halt triple‑negative breast cancer via p53‑PPARα/PI3K‑Akt pathway suppression.
Int J Oncol
November 2025
Department of Ultrasound, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.
Triple‑negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options, leading to poor clinical outcomes and the need for novel therapeutic approaches. Nintedanib, a United States Food and Drug Administration‑approved multi‑kinase inhibitor with anti‑fibrotic and anti‑angiogenic properties, has shown promise in cancer treatment. However, its precise molecular effects on TNBC have not yet been fully elucidated.
View Article and Find Full Text PDF